Bharat Biotech ramping up manufacturing capacity to 70 Cr doses: Dr. Raches Ella
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Subscribe To Our Newsletter & Stay Updated